Long-term results of fi rst salvage treatment in CLL patients treated initially with FCR ( fl udarabine , cyclophosphamide , rituximab )
暂无分享,去创建一个
K. Do | H. Kantarjian | J. Cortes | W. Plunkett | M. Keating | S. O'brien | C. Tam | Xuemei Wang | W. Wierda | A. Ferrajoli | S. Lerner | I. Khouri
[1] Michael Hallek,et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. , 2014, The New England journal of medicine.
[2] A. Zelenetz,et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. , 2014, The New England journal of medicine.
[3] Juthamas Sukbuntherng,et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. , 2013, The New England journal of medicine.
[4] L. Lam,et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets , 2013, Nature Medicine.
[5] C. Tam,et al. Diagnostic techniques and therapeutic challenges in patients with TP53 dysfunctional chronic lymphocytic leukemia , 2012, Leukemia & lymphoma.
[6] J. Gribben,et al. Risk categories and refractory CLL in the era of chemoimmunotherapy. , 2012, Blood.
[7] Hao Xiong,et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] E. Montserrat,et al. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] A. Bagg,et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.
[10] A. Berrebi,et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial , 2010, The Lancet.
[11] K. Do,et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. , 2008, Blood.
[12] Michael Hallek,et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.
[13] M. Andreeff,et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Ash A. Alizadeh,et al. Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. , 2004, Blood.
[15] Leo Breiman,et al. Classification and Regression Trees , 1984 .
[16] N. Mantel. Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.
[17] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[18] E. Kimby,et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus , 2007, Leukemia.
[19] David R. Cox,et al. Regression models and life tables (with discussion , 1972 .